Why would any investor even entertain thinking that a call questioning the abilities of the CEO to move XXII to the forefront is in fact a reach.
VLNT protected via numerous patents has been a slow mover at best due to the snail pace of governmental beauracracy of the FDA. Why hasn't the company move their products overseas? A question this forum member and others have asked repeatedly on IHUB?
Corporate's lazer focus on promoting VLNT in the US has been tied up for far too long imo. What exactly has been corporate's focus on a single agenda leaving very little on the HEMP and CBD I/P PORTFOLIO held by XXII.
One should give their head a shake if anyone could convey that to XXII corporate during a conference call and receive plausible answers today or any day.
Market Data 
Markets 
AI
